



Sprint Bioscience

Økonomisk Ugebrev, February 28, 2024

PRESSRELEASE

Sprint Bioscience licenses the VADA (VRK1) program to Day One Biopharmaceuticals

16 AUG. 2023 14:00:00

Regulatory

Sprint Bioscience AB (publ) has licensed the global rights to its cancer program VADA (VRK1) to Day One Biopharmaceuticals Inc. The total potential value of the agreement amounts to US\$ 316 million plus single-digit royalties on sales of a future drug from the program. Upon entering into the agreement, Sprint Bioscience will receive an upfront payment of US\$ 3 million. In addition, Sprint Bioscience will project-lead the program and be reimbursed for continuing preclinical research and development activities in the coming two years.

Total Potential Value
US\$ 316 Million + Royalties

Upfront Received
US\$ 3 Million

Reimbursement for continued research
2023-2025

US\$ ~2 Million
August-December 2023

FINANCES – YEAR END 2023

50.5 MSEK

REVENUES 2023


-0.8 MSEK

EBIT 2023

49.9 MSEK

CASH BALANCE END 2023


INCREASING REVENUES AFTER LIMITED INITIAL INVESTMENT



EARLY PHASE CANCER PROGRAMS

OVERALL LOW RESPONSE TO IMMUNOTHERAPY


All US cancer patients




Ref: Haslam & Prasad, JAMA Network Open, 2020

COMBINATION TREATMENTS TO INCREASE RESPONSE


Increased response by combinations



SMALL MOLECULE PLATFORM DELIVERS PRECISION MEDICINE




PIPELINE



INTERNAL PROGRAMS

DISA & NIMA

FOCUS AREAS ONCOLOGY



INTERNAL PROGRAMS CURRENTLY PERSUED FOR LICENSING


DISA - improved response to immunotherapy

- Target protein TREX1
- Up-regulation of TREX1 involved immunotherapy resistance
- TREX1 inhibition leads to immune cell infiltration and activation

PRESSRELEASE

Sprint Bioscience's DISA program further validated in two recent scientific publications


22 JAN. 2024 13:30:00



INTERNAL PROGRAMS CURRENTLY PERSUED FOR LICENSING

NIMA - targeting multiple tumor growth mechanisms


- Target protein: NNMT “Tumor multitool”
- Monotherapy
- Combination therapy
 - Immunotherapy
 - Cytostatics



DEAL-MAKING ACTIVITY

Licensing statistics for 2023

DISCOVERY-STAGE DEAL MAKING DURING 2023



Ref: Pullan's pieces #198, pharma/biotech news and analysis



We are a sustainable
profitable growth
company focused on
developing early-stage
cancer drug programs

A photograph of two female scientists in a laboratory. They are wearing white lab coats with the 'Sprint Bioscience' logo and safety goggles. The scientist on the left is holding a tablet and pointing at it, while the scientist on the right looks on. The background is a blurred laboratory setting with blue lighting.

Unique platform

Proven business model

Strong pipeline